New hope for advanced nose and throat cancer: drug combo trial launches
NCT ID NCT07258979
First seen Jan 08, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests a new drug (YL201) combined with an immunotherapy (toripalimab), with or without chemotherapy (cisplatin), in people whose nasopharyngeal cancer has come back or spread. The goal is to see if the combination is safe and helps control the cancer. About 202 adults with advanced disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact
-
Chongqing University Cancer Hospital
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, China
Contact
-
Dongguan People's Hospital
NOT_YET_RECRUITINGDongguan, Guangdong, China
Contact
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Fujian Cancer Hospital
NOT_YET_RECRUITINGFuzhou, Fujian, China
Contact
-
Guangxi Medical University Cancer Hospital
NOT_YET_RECRUITINGNanning, Guangxi, China
Contact
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact
-
Jiangmen Central Hospital
NOT_YET_RECRUITINGJiangmen, Guangdong, China
Contact
-
Jiangxi Cancer Hospital
NOT_YET_RECRUITINGNanchang, Jiangxi, China
Contact
-
Sichuan Cancer Hospital
NOT_YET_RECRUITINGChengdu, Sichuan, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
-
The First Affiliated Hospital of Guangdong Pharmaceutical University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact
-
The First Affiliated Hospital of Hainan Medical University
NOT_YET_RECRUITINGHaikou, Hainan, China
Contact
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, China
Contact
-
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITINGXiamen, Fujian, China
Contact
-
The Second Affiliated Hospital of Guilin Medical University
NOT_YET_RECRUITINGGuilin, Guangxi, China
Contact
-
Yuebei People's Hospital
NOT_YET_RECRUITINGShaoguan, Guangdong, China
Contact
-
Yunnan Cancer Hospital
NOT_YET_RECRUITINGKunming, Yunnan, China
Contact
-
Zhangzhou Municiple Hospital of Fujian Province
NOT_YET_RECRUITINGZhangzhou, Fujian, China
Contact
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
Contact
Conditions
Explore the condition pages connected to this study.